FDA clears Abbott’s Libre Duo 10-Day sensor to warn of diabetic ketoacidosis

The U.S. Food and Drug Administration has cleared Abbott’s new wearable device that measures both glucose and ketone levels in people with diabetes. The clearance allows the product to be marketed in the United States later this year.

The sensor provides continuous glucose monitoring while also detecting rising ketone concentrations, which can signal the onset of diabetic ketoacidosis. Users receive alerts when ketone levels increase, giving them an early warning to take corrective action.

Designed for individuals aged two and older, the device can be worn for up to ten days on a single patch. Abbott’s executive vice president highlighted that combining glucose and ketone data offers a more complete view of diabetes management, helping patients make more informed decisions.